| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 3 | +66.67% | +6.91% | -0.65% | +7.56% | +4.91% | — |
| 14d | 3 | +33.33% | +10.56% | -0.13% | +10.69% | -1.74% | — |
| 30d | 3 | +33.33% | +23.59% | -1.02% | +24.61% | -9.29% | — |
| 60d | 3 | +33.33% | -8.56% | -2.56% | -6.00% | -14.34% | — |
| 90d | 3 | +33.33% | -7.88% | +0.13% | -8.01% | -28.79% | — |
| 180d | 3 | +0.00% | -38.60% | +5.88% | -44.48% | -27.30% | — |
| 1y | 3(2 pending) | +0.00% | -9.02% | +12.15% | -21.18% | -21.18% | — |
| 2y | 3(3 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| AARD AARDVARK THERAPEUTICS, INC. | SALEGRANT Stock grant | 70,549 | — | — | 70,549 | Feb 9, 2026 | Feb 11, 2026 ↗ | View → |
| AARD AARDVARK THERAPEUTICS, INC. | PURCHASE Chief Financial Officer | 3,000 | $14.40 | $43.2K | 108,484 | Dec 11, 2025 | Dec 12, 2025 ↗ | View → |
| AARD AARDVARK THERAPEUTICS, INC. | PURCHASE Chief Financial Officer | 6,000 | $8.07 | $48.4K | 105,484 | Sep 9, 2025 | Sep 10, 2025 ↗ | View → |
| AARD AARDVARK THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 209,826 | — | — | 209,826 | Jun 11, 2025 | Jun 13, 2025 ↗ | View → |
| AARD AARDVARK THERAPEUTICS, INC. | PURCHASE Chief Financial Officer | 7,001 | — | — | 89,484 | Feb 14, 2025 | Feb 19, 2025 ↗ | View → |
| AARD AARDVARK THERAPEUTICS, INC. | PURCHASE Chief Financial Officer | 10,000 | $16.00 | $160.0K | 99,484 | Feb 14, 2025 | Feb 19, 2025 ↗ | View → |
| AARD AARDVARK THERAPEUTICS, INC. | SALE Chief Financial Officer | 59,332 | — | — | 0 | Feb 14, 2025 | Feb 19, 2025 ↗ | View → |